SBC Medical Group Holdings Incorporated financials
$4.84−3.78%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Fiscal year | FY25 Dec 31 | FY24 Dec 31 | FY23 Dec 31 | FY22 Dec 31 | FY21 Dec 31 | FY20 Dec 31 | FY19 Dec 31 | FY18 Dec 31 | FY17 Dec 31 | FY16 Dec 31 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $173.6M | $205.4M | $122.43B | $120.74B | $134.04B | $143.05B | $181.19B | $170.76B | $160.55B | $163.79B |
| Gross profit | $127.3M | $156.1M | $72.31B | $69.89B | $73.63B | $77.40B | $97.05B | $91.34B | $82.74B | $86.60B |
| Gross margin | 73.3% | 76.0% | 59.1% | 57.9% | 54.9% | 54.1% | 53.6% | 53.5% | 51.5% | 52.9% |
| Operating income | $67.5M | $70.3M | $23.46B | -$4.59B | $25.90B | $8.37B | $27.95B | $26.10B | $19.97B | $23.54B |
| Net income | $51.0M | $46.6M | $14.19B | -$8.06B | $19.87B | -$5.37B | $13.90B | $19.37B | $29.45B | $12.98B |
| Net margin | 29.4% | 22.7% | 11.6% | −6.7% | 14.8% | −3.8% | 7.7% | 11.3% | 18.3% | 7.9% |
| Diluted EPS | $0.50 | $0.48 | $1.97 | $-1.13 | $2.73 | $-0.75 | $1.89 | $2.85 | $4.76 | $2.10 |
| EBITDA | $70.2M | $89.2M | $43.43B | $40.93B | $43.96B | $46.58B | $67.22B | $58.34B | $47.27B | $49.75B |
| Operating cash flow | $24.7M | $20.6M | $38.31B | $32.02B | $41.96B | $43.13B | $48.67B | $43.60B | $38.01B | $38.44B |
| Free cash flow | $22.3M | $17.2M | $20.46B | $12.40B | $26.41B | $28.44B | $29.03B | $22.35B | $16.46B | $16.93B |
| Diluted shares | 103.0M | 96.6M | 7,258.0M | 7,587.0M | 7,503.0M | 7,183.0M | 7,348.0M | 6,806.0M | 6,183.0M | 6,180.0M |
Balance sheet
| Period end | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $163.8M | $125.0M | $6.72B | $3.70B | $19.22B | $9.74B |
| Short-term investments | $13.2M | $6.0M | $0.00 | $0.00 | — | — |
| Total debt | $43.1M | $6.6M | $137.33B | $135.89B | $175.63B | $157.25B |
| Total assets | $380.4M | $266.1M | $407.06B | $402.85B | $551.62B | $525.76B |
| Total liabilities | $117.1M | $71.1M | $287.64B | $296.40B | $367.77B | $346.52B |
| Shareholders' equity | $263.3M | $195.0M | $117.44B | $106.46B | $183.85B | $179.24B |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology